PDCD1 and hepatocellular carcinoma: Among these, a combination of anti-PD1 with SP94-PB-sorafenib-Cy5.5 nanoparticles, a tyrosine kinase inhibitor (TKI), plus near-infrared therapy has shown suppression of distant metastases [176] and, in patients with early HCC recurrence after radical resection, TKI plus PD-1 therapy had shown survival benefit [177].